Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANG-3777 QT/QTc Study in Healthy Volunteers
NCT04898907Phase 1Unknown
- Sponsor
- Angion Biomedica Corp.
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of terevalefim in delayed graft function (DGF) and acute kidney injury (AKI) (4 arms), sponsored by Angion Biomedica Corp. Primary endpoint: Change from baseline in corrected QT interval by Fridericia's formula at Day 13. Status: unknown.
02
Drugs
terevalefim
03
Conditions
delayed graft function (DGF)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04898907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898907.